Zobrazeno 1 - 10
of 99
pro vyhledávání: '"Eugene Ahn"'
Autor:
Kiwoon Baeg, Cynthia Harris, Monica S. Naparst, Eugene Ahn, Sahityasri Thapi, Jacob Martin, Sheila Rustgi, Grace Mhango, Juan Wisnivesky, Michelle Kang Kim
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Abstract Background Medical centers with varying levels of expertise treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which are relatively rare tumors. This study assesses the impact of center volume on GEP-NET treatment outcomes. Metho
Externí odkaz:
https://doaj.org/article/5f5cf7af3c844387a7a83ad1aa631fa1
Autor:
Brian Van Tine, Eugene Ahn, John Powderly, Herbert Duvivier, Drew Rasco, Rebecca Redman, Steven Powell, Agnes Rethy, Chris Moore, Amy Yuet, Rachael Orlandella, Swati Khanna, David Spigel, Angela Georgy, Joseph Dekker
Publikováno v:
Regular and Young Investigator Award Abstracts.
Autor:
Bowles Daniel W, Lyudmila Bazhenova, Segolene Hescot, Gunnar Folprecht, Haruko Daga, Erminia Massarelli, Conley Anthony P, Livia Lamartina, Jessica Lin, Eugene Ahn, Stuart Osborne, Sebastian Heinzmann, Daniel Carrizosa
Publikováno v:
Endocrine Abstracts.
Autor:
Monica Naparst, Naomi Alpert, Michelle K. Kim, Kelly E Diaz, Emanuela Taioli, Elizabeth Kessel, Eugene Ahn, Edward M. Wolin
Publikováno v:
Pancreas. 50:29-36
Objectives The objective of this study was to evaluate racial differences in cancer treatment and survival in gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients. Methods Using the Surveillance, Epidemiology, and End Results Registry, we i
Autor:
David R. Spigel, Eugene Ahn, Herbert L. Duvivier, Drew Rasco, Agnes Rethy, Chris Moore, Amy Yuet, Sandra Hankins, Swati Khanna, Joseph Dekker, Brian Van Tine
Publikováno v:
Cancer Research. 82:CT152-CT152
This is the first-in-human study of MT-6402, a unique, first-in-class potent PD-L1-targeted engineered toxin body (ETB) capable of direct killing of PD-L1 expressing cells via rapid PD-L1-mediated internalization of a fused Shiga-like toxin A subunit
Autor:
Sahityasri Thapi, Eugene Ahn, Kiwoon Joshua Baeg, Cynthia K. Harris, Sheila D. Rustgi, Juan P. Wisnivesky, Grace Mhango, Michelle K. Kim, Monica Naparst, Jacob A. Martin
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-7 (2021)
Background Medical centers with varying levels of expertise treat gastroenteropancreatic neuroendocrine tumors (GEP-NETs), which are relatively rare tumors. This study assesses the impact of center volume on GEP-NET treatment outcomes. Methods We use
Autor:
Nitin Rohatgi, Elizabeth Garrett-Mayer, Omid Hamid, Monika L. Burness, Alison Conlin, Jordi Rodon, Richard L. Schilsky, Michael Rothe, Ramya Thota, Philip Gold, Keerthi Gogineni, Pam K. Mangat, Anu G. Gaba, Eugene Ahn, Carmen Calfa, Tareq Albaghdadi
Publikováno v:
Cancer Research. 81:CT173-CT173
Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. S is an oral multi-kinase inhibitor that inhibits Fibroblast Growth Factor Re
Autor:
Richard L. Schilsky, Michael L. Maitland, Apostolia Maria Tsimberidou, Sapna R. Patel, Liz Garrett-Mayer, Pam K. Mangat, Eugene Ahn, Ani Sarkis Balmanoukian, Charles A. Leath, Michael Rothe, Hussein Moustapha Ali-Ahmad, Zachary L Reese, John K. Chan, Rui Li, Charles W. Drescher
Publikováno v:
Journal of Clinical Oncology. 39:5508-5508
5508 Background: TAPUR is a phase II basket study evaluating anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations. Results in a cohort of UC pts with ERBB2 or ERBB3 amplification , overex
Autor:
Emanuela Taioli, Edward M. Wolin, Michelle K. Kim, Elizabeth Kessel, Naomi Alpert, Monica Naparst, Eugene Ahn
Publikováno v:
Gastroenterology. 158:S-292
Autor:
J. Antunez de Mayolo, Cory Patrick, B. McIntyre, J. Cutler, F. Farooq, K. Feister, K. McIntyre, Eugene Ahn, Damien Hansra, Jeremy Ramdial, Stuart Sacks, M. Miller, A. K. Taylor
Publikováno v:
Evidence-based Complementary and Alternative Medicine : eCAM
Evidence-Based Complementary and Alternative Medicine, Vol 2018 (2018)
Evidence-Based Complementary and Alternative Medicine, Vol 2018 (2018)
Evidence regarding opinions on integrative modalities by patients and physicians is lacking.Methods. A survey study was conducted assessing how integrative modalities were valued among hematology/oncology patients and hematologists and oncologists at